Labcorp expands use of digital pathology with renewed PathAI partnership
Labcorp is accelerating its adoption of artificial intelligence through its core business of primary laboratory diagnostics, announcing last week an expanded agreement with PathAI to further deploy a platform that will support digital workflows and assist with diagnostics
The agreement would mean the AI-backed diagnostic capabilities will be at more Labcorp labs, including those inside hospitals.
Under the updated collaboration, the company will implement PathAI’s AISight Dx platform, allowing for most lab workflows to be conducted digitally—including the review of specimens, effectively eliminating the need for glass slides.
Instead, slides are scanned into the system, where multiple pathologists can review them as high-resolution images, even from different locations. Remote consultation is also readily available through the platform interface to support situations where patients have multiple specimens sent to different labs.
All of this is facilitated by secure data transfers and full integration with existing systems. The goal is to improve not only turnaround times but the accuracy of all diagnostic readings.
The expansion builds on a relationship that began in 2019, when North Carolina-based Labcorp first invested in then-startup PathAI, which was founded only three years prior. Two years later, the diagnostics giant broadened its use of the technology to support clinical trials.
At the time, PathAI described the partnership as a step toward integrating its AI-enabled pathology tools into routine clinical laboratory practice. With the nationwide rollout of AISight Dx, that is now a reality, as Labcorp is effectively adopting the technology for all diagnostic settings.
Labcorp said the deployment will allow it to scale digital pathology across its U.S. network while integrating AI-generated insights into everyday case review.
"Labcorp is committed to building a modern, AI-powered infrastructure that sets a new standard for efficiency, collaboration and innovation in pathology," Marcia Eisenberg, PhD, chief scientific officer at Labcorp, said in a statement. "PathAI's technology allows us to scale digital pathology nationwide and integrate AI insights into routine care—delivering faster, more consistent results for patients and providers."
The move puts the publicly traded company in closer alignment with its main competitor, Quest Diagnostics, which licensed AISight Dx in 2024 as part of a $100 million acquisition of PathAI’s Memphis-based diagnostic laboratory operations.
Regulatory flexibility credited for improvements
AISight Dx previously received clearance from the U.S. Food and Drug Administration in 2022. A subsequent 510(k) clearance granted in 2025 allows PathAI to validate and implement certain major updates—including additional display systems, scanners, file formats and web browsers—without seeking new FDA review for each modification.
The regulatory flexibility could streamline future upgrades as the technology evolves, the company said.
Chad is an award-winning writer and editor with over 15 years of experience working in media. He has a decade-long professional background in healthcare, working as a writer and in public relations.